Kura Oncology, Inc.
In this clinical trial, the safety, tolerability, and preliminary antitumor activity of ziftomenib in combination with imatinib will be evaluated in adults with gastrointestinal stromal tumors (GIST) who have been treated previously with imatinib as current or prior therapy, or are treatment naive.
Key Inclusion Criteria: * Documented diagnosis of advanced/metastatic KIT-mutant GIST * Documented disease progression on imatinib as current or prior therapy or is treatment naïve, as follows: * DES: Participant is progressing or progressed on imatinib in any prior line of therapy. * EXP Cohort A: Participant is progressing or progressed on imatinib and has not received additional intervening therapy before study participation. * EXP Cohort B: Participant has progressed on imatinib and sunitinib only and has not received additional intervening therapy before study participation. * E…
menin inhibitor
kinase inhibitor